Market Overview

UPDATE: Credit Suisse Assumes Coverage on Quest Diagnostics with Neutral Rating, $67 PT

Share:
Related DGX
Earnings Scheduled For January 26, 2017
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector

In a report published Friday, Credit Suisse assumed coverage on Quest Diagnostics (NYSE: DGX) with a Neutral rating and $67.00 price target.

Credit Suisse noted, “We are assuming coverage of DGX with a Neutral rating (previously Outperform). Recall DGX is the largest independent clinical laboratory in the U.S. We acknowledge the company & new management have an opportunity to offset some of the anemic top-line trends and close the margin gap relative to LH which could aid the earnings growth profile. Moreover strong cash flows & greater clarity this fall on plans to return value to shareholders should support valuation. However, trading at 12.4x our new F13 estimates on a P/E basis and 7.8x on an EV/EBITDA basis, and having outperformed industry & healthcare services peers YTD, we believe the current risk/reward profile is more balanced. We are increasing our estimates and maintaining our TP of $67.”

Quest Diagnostics closed on Thursday at $62.19.

Latest Ratings for DGX

DateFirmActionFromTo
Mar 2017Bank of AmericaUpgradesUnderperformNeutral
Jan 2017Deutsche BankInitiates Coverage OnBuy
Jan 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!